Multimedia

Multimedia

Podcasts and video interviews with researchers, commentators, and experts in the field

video

Expanding Acalabrutinib to Waldenström Macroglobulinemia

Roger Owen, MRCP, MRCPath, MD, presents phase II data of the selective Bruton tyrosine kinase inhibitor, which showed “exceptional response rates” in both treatment-naïve...
video

Weekly Carfilzomib Dosing Superior to Twice-Weekly Dosing

James Berenson, MD, discusses results from a trial evaluating less-frequent dosing of carfilzomib for patients with myeloma. Once-weekly dosing was superior, but the mechanisms...
video

Enhancing Ibrutinib With Rituximab in Waldenström Macroglobulinemia

Combining ibrutinib with rituximab led to longer progression-free survival, compared with ibrutinib alone, in patients with Waldenström macroglobulinemia. Meletios Dimopoulos, MD, shares results from...
video

Does Blinatumomab Affect CAR T-Cell Therapy Response?

In new data from ZUMA-3, patients with acute lymphocytic leukemia responded to CD19-targeting CAR T-cell therapy, regardless of prior CD19-targeting therapy with blinatumomab. Bijal...
video

Venetoclax Plus Carfilzomib: A New Wave of Myeloma Treatment

Luciano Costa, MD, talks about the combination of venetoclax and carfilzomib, which led to an 83% response rate in patients with relapsed and heavily-refractory...
video

With bb2121, Is CAR T-Cell Therapy Ready for Myeloma?

Noopur Raje, MD, discusses updated data from a phase I trial of the second-generation, anti-BCMA CAR T-cell therapy for relapsed/refractory myeloma.
video

“Best Survival Data Yet” With Nelarabine in T-Cell ALL

Kimberly P. Dunsmore, MD, discusses results from the largest trial conducted of young patients with newly diagnosed T-cell acute lymphocytic leukemia, which produced survival...
video

Positive Results With Ivosidenib in IDH1-Mutated AML

Treatment with the highly selective IDH1 inhibitor ivosidenib led to a complete remission rate of 40%, with an overall survival of nearly 19 months...
video

Allogeneic Transplant Plus NK Cells in High-Risk Myeloma

Dr. Shah discusses natural killer cells for myeloma - a cellular therapy that "kills" without causing graft-versus-host disease.
video

Evaluating New Myeloma Agent Combinations in Lenalidomide-Refractory Patients

Dr. Chari reports results from a trial of daratumumab plus carfilzomib-dexamethasone in patients with lenalidomide-refractory disease.
Advertisement

Current Issue

September 2018, Volume 4, Issue 11

View issue flipbook September 2018 Volume 4, Issue 11This issue features a look at research misconduct, a debate about whether chronic lymphocytic leukemia is curable, and...